Nakajima K - Search Results

1

Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management.

Nakajima K, Kho DH, Yanagawa T, Zimel M, Heath E, Hogan V, Raz A. Nakajima K, et al. Cancer Metastasis Rev. 2016 Jun;35(2):333-46. doi: 10.1007/s10555-016-9622-4. Cancer Metastasis Rev. 2016. PMID: 27067726 Free PMC article. Review.

2

Why anti-Bcl-2 clinical trials fail: a solution.

Harazono Y, Nakajima K, Raz A. Harazono Y, et al. Among authors: nakajima k. Cancer Metastasis Rev. 2014 Mar;33(1):285-94. doi: 10.1007/s10555-013-9450-8. Cancer Metastasis Rev. 2014. PMID: 24338002 Free PMC article. Review.

3

Galectin-3 inhibits osteoblast differentiation through notch signaling.

Nakajima K, Kho DH, Yanagawa T, Harazono Y, Gao X, Hogan V, Raz A. Nakajima K, et al. Neoplasia. 2014 Nov 20;16(11):939-49. doi: 10.1016/j.neo.2014.09.005. eCollection 2014 Nov. Neoplasia. 2014. PMID: 25425968 Free PMC article.

4

Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.

Nakajima K, Kho DH, Yanagawa T, Harazono Y, Hogan V, Chen W, Ali-Fehmi R, Mehra R, Raz A. Nakajima K, et al. Cancer Res. 2016 Mar 15;76(6):1391-402. doi: 10.1158/0008-5472.CAN-15-1793. Epub 2016 Feb 2. Cancer Res. 2016. PMID: 26837763 Free PMC article.

5

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients.

Nakajima K, Balan V, Raz A. Nakajima K, et al. Cancer Metastasis Rev. 2021 Mar;40(1):297-302. doi: 10.1007/s10555-020-09932-4. Epub 2020 Sep 14. Cancer Metastasis Rev. 2021. PMID: 32929561 Free PMC article. Review.

6

Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling.

Harazono Y, Kho DH, Balan V, Nakajima K, Hogan V, Raz A. Harazono Y, et al. Among authors: nakajima k. Oncotarget. 2015 Aug 14;6(23):19592-604. doi: 10.18632/oncotarget.4285. Oncotarget. 2015. PMID: 26158764 Free PMC article.

7

Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.

Nakajima K, Heilbrun LK, Hogan V, Smith D, Heath E, Raz A. Nakajima K, et al. Oncotarget. 2016 Dec 13;7(50):82266-82272. doi: 10.18632/oncotarget.12619. Oncotarget. 2016. PMID: 27741512 Free PMC article.

8

The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II.

Nakajima K, Heilbrun LK, Smith D, Hogan V, Raz A, Heath E. Nakajima K, et al. Oncotarget. 2017 Mar 14;8(11):17643-17650. doi: 10.18632/oncotarget.12620. Oncotarget. 2017. PMID: 27741522 Free PMC article. Clinical Trial.

9

Cancer Self-Defense: An Immune Stealth.

Nakajima K, Nangia-Makker P, Hogan V, Raz A. Nakajima K, et al. Cancer Res. 2017 Oct 15;77(20):5441-5444. doi: 10.1158/0008-5472.CAN-17-1324. Epub 2017 Aug 24. Cancer Res. 2017. PMID: 28838888 Free PMC article. Review.

10

Autocrine motility factor and its receptor expression in musculoskeletal tumors.

Nakajima K, Raz A. Nakajima K, et al. J Bone Oncol. 2020 Sep 14;24:100318. doi: 10.1016/j.jbo.2020.100318. eCollection 2020 Oct. J Bone Oncol. 2020. PMID: 33101887 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,085 results

Search Page

Filters